Valneva Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 3/6

Valneva hat ein Gesamteigenkapital von €217.5M und eine Gesamtverschuldung von €172.6M, was einen Verschuldungsgrad von 79.4% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen €516.6M bzw. €299.1M.

Wichtige Informationen

79.4%

Verhältnis von Schulden zu Eigenkapital

€172.58m

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	€156.34m
Eigenkapital	€217.47m
Gesamtverbindlichkeiten	€299.15m
Gesamtvermögen	€516.61m

Jüngste Berichte zur Finanzlage

Recent updates

Valneva SE's (EPA:VLA) 25% Dip In Price Shows Sentiment Is Matching Revenues

Nov 22

€6.97: That's What Analysts Think Valneva SE (EPA:VLA) Is Worth After Its Latest Results

Nov 10

Revenues Working Against Valneva SE's (EPA:VLA) Share Price Following 29% Dive

Sep 19

Valneva SE (EPA:VLA) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Aug 17

Valneva SE (EPA:VLA) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 10

Valneva SE's (EPA:VLA) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Apr 05

Analyst Forecasts Just Became More Bearish On Valneva SE (EPA:VLA)

Mar 27

Is Valneva (EPA:VLA) Weighed On By Its Debt Load?

Mar 15

News Flash: Analysts Just Made A Captivating Upgrade To Their Valneva SE (EPA:VLA) Forecasts

Jan 06

Valneva (EPA:VLA) Has Debt But No Earnings; Should You Worry?

Dec 13

Does Valneva (EPA:VLA) Have A Healthy Balance Sheet?

Aug 10

Valneva SE's (EPA:VLA) Business And Shares Still Trailing The Industry

May 12

Valneva (EPA:VLA) Takes On Some Risk With Its Use Of Debt

Jan 30

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: VLADie kurzfristigen Aktiva des Unternehmens (€303.6M) übersteigen seine kurzfristigen Passiva (€109.2M).

Langfristige Verbindlichkeiten: VLADie kurzfristigen Vermögenswerte des Unternehmens (€303.6M) übersteigen seine langfristigen Verbindlichkeiten (€190.0M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: VLADie Nettoverschuldung im Verhältnis zum Eigenkapital (7.5%) wird als zufriedenstellend angesehen.

Schulden abbauen: VLADas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 19.6% auf 79.4% gestiegen.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: VLA hat auf der Grundlage seines derzeitigen freier Cashflows weniger als ein Jahr Liquiditätsspielraum.

Vorhersage Cash Runway: Unzureichende Daten, um festzustellen, ob VLA über genügend Cash Runway verfügt, wenn sein freier Cashflow auf der Grundlage historischer Raten weiter wächst oder schrumpft.

Valneva Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Is Valneva (EPA:VLA) Weighed On By Its Debt Load?

Valneva (EPA:VLA) Has Debt But No Earnings; Should You Worry?

Does Valneva (EPA:VLA) Have A Healthy Balance Sheet?

Valneva (EPA:VLA) Takes On Some Risk With Its Use Of Debt

Recent updates

Valneva SE's (EPA:VLA) 25% Dip In Price Shows Sentiment Is Matching Revenues

Consensus EPS estimates increase from loss to €0.08 profit

Price target decreased by 7.4% to €6.83

Valneva and LimmaTech Announces First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2

Forecast to breakeven in 2024

€6.97: That's What Analysts Think Valneva SE (EPA:VLA) Is Worth After Its Latest Results

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

New minor risk - Financial position

Valneva SE to Report Nine Months, 2025 Results on Nov 13, 2025

Valneva SE and LimmaTech Biologics AG Receives FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V

Revenues Working Against Valneva SE's (EPA:VLA) Share Price Following 29% Dive

Price target decreased by 11% to €7.68

New minor risk - Shareholder dilution

Valneva SE and Pfizer Inc. Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate

Valneva SE (EPA:VLA) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Consensus EPS estimates fall from profit to €0.05 loss

Second quarter 2024 earnings released: €0.19 loss per share (vs €0.12 loss in 2Q 2023)

No longer forecast to breakeven

Consensus EPS estimates fall by 75%

Valneva SE Receives Marketing Authorization in Europe for the World's First Chikungunya Vaccine, Ixchiq

Valneva SE Appoints Daniele Guyot-Caparros as Board of Directors

Valneva SE (EPA:VLA) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

First quarter 2024 earnings released: EPS: €0.42 (vs €0.13 loss in 1Q 2023)

Valneva SE Confirms Earnings Guidance for the Fiscal Year 2024

Valneva SE's (EPA:VLA) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Analyst Forecasts Just Became More Bearish On Valneva SE (EPA:VLA)

Valneva SE Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate

Full year 2023 earnings released: €0.73 loss per share (vs €1.24 loss in FY 2022)

New minor risk - Profitability

Is Valneva (EPA:VLA) Weighed On By Its Debt Load?

U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ

Consensus EPS estimates fall by 19%

Forecast to breakeven in 2024

Valneva Se Announces Earnings Guidance for 2024

Consensus EPS estimates upgraded to €0.05 loss

Consensus EPS estimates fall by 103%

Price target decreased by 8.6% to €9.17

Valneva Se Announces the First Participant Has Been Vaccinated in the Phase 2 Clinical Trial Evaluating the Safety and Immunogenicity in Children of Two Different Dose Levels of Valneva’S Single-Shot Chikungunya Vaccine

Valneva SE to Report Fiscal Year 2023 Results on Mar 21, 2024

News Flash: Analysts Just Made A Captivating Upgrade To Their Valneva SE (EPA:VLA) Forecasts

Valneva SE Revises Earnings Guidance for the Full Year 2023

Valneva SE Revises Earnings Guidance for the Full Year 2023

Valneva SE to Report Q1, 2024 Results on May 07, 2024

No longer forecast to breakeven

Valneva (EPA:VLA) Has Debt But No Earnings; Should You Worry?

Valneva SE reported positive antibody persistence data twenty-four months after vaccination with a single dose of its chikungunya vaccine IXCHIQ®

Ema Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment

Ema Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment

Valneva SE Announces Board Changes

New minor risk - Financial position

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Valneva SE Announces U.S. FDA Approval of World's First Chikungunya Vaccine, IXCHIQ(R)

Consensus EPS estimates upgraded to €0.12 loss

Valneva Se Provides Revenue Guidance for the Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Valneva SE Announces Positive Pediatric and Adolescent Immunogenicity and Safety Data for Their Lyme Disease Vaccine Candidate, VLA15

Health Canada Accepts Valneva's Chikungunya Vaccine License Application for Review

Valneva SE Reports Positive Initial Phase 3 Safety Data in Adolescents for Its Single-Shot Chikungunya Vaccine Candidate Vla1553

Valneva SE announced a financing transaction

Does Valneva (EPA:VLA) Have A Healthy Balance Sheet?

Valneva Se Appoints Kathrin U Jansen to Supervisory Board

Price target increased by 8.3% to €9.73

Forecast breakeven date moved forward to 2023

Valneva SE Announces Publication of its Chikungunya Vaccine Candidate Phase 3 Data in the Lancet

Valneva SE's (EPA:VLA) Business And Shares Still Trailing The Industry

Valneva SE Provides Financial Guidance of 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

No longer forecast to breakeven

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Pfizer Inc. and Valneva SE Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15

Valneva Completes Enrollment for Adolescent Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate